Amgen beats analysts’ revenue, earnings per share estimates
Amgen revenues increased 2 percent during the third quarter as it beat analysts’ revenue and earnings per share estimates thanks to cost-cutting measures and lower research measures. Revenues for the Thousand Oaks-based biotech giant increased from $5.72 billion during the third quarter of 2015 to $5.81 billion in 2016, which beat analyst estimates of $5.73 Read More →
Read More →Proposition 61 will not cure sky high drug prices
Proposition 61 goes before California voters in just a few weeks. And as the Business Times reported on Oct. 14, Amgen, the Thousand Oaks-based biotech giant, along with other major drug companies, is spending millions to oppose Proposition 61 and its plan to control drug prices. Proponents promote the David vs. Goliath aspect of their Read More →
Read More →Amgen to pay $1 quarterly dividend
Thousand Oaks-based biotech giant Amgen announced another quarterly dividend of $1 per share Oct. 14 for the fourth quarter of 2016. The dividend will be paid on Dec. 8, 2016, to all stockholders of record as of the close of business on Nov. 16, 2016. • Contact Philip Joens at pjoens@pacbiztimes.com.
Read More →
Amgen spends big to defeat Proposition 61
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen sells Colorado facility to AstraZeneca for $64.5 million
Thousand Oaks biotech giant Amgen continued its Colorado exit plans recently as it sold a Longmont, Colo., facility to London-based pharmaceutical and biotech company AstraZeneca for $64.5 million. Amgen built the 692,000-square-foot facility in the 1990s to make ingredients for its blockbuster anti-anemia drug Epogen. The site used large vats to produce lines of cell Read More →
Read More →Amgen partners with Swedish company to develop drugs
Thousand Oaks-based Amgen will pay a Swedish company up to $410 million to help it develop oncology and neuroscience drugs. The companies announced the partnership Oct. 4 and said Nuevolution will use its Chemetics drug discovery platform to discover drugs for Amgen. Nuevolution may receive licensing payments along with development, commercial and milestone payments. It Read More →
Read More →Amgen leukemia drug cures 39 percent of treated patients, study finds
Amgen’s new leukemia drug cured 39 percent of pediatric patients who received treatment, the Thousand Oaks company said Oct. 3 after publishing results of a new study in the Journal of Clinical Oncology. Blincyto, which treats a rare form of the disease known as precursor B-cell acute lymphoblastic leukemia, sent 27 patients out of 70 Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
